Literature DB >> 3841027

Infarct size limitation by the xanthine oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts.

S Akizuki, S Yoshida, D E Chambers, L J Eddy, L F Parmley, D M Yellon, J M Downey.   

Abstract

The present study was designed to evaluate the ability of allopurinol to limit infarct size following permanent coronary occlusion in the greyhound. Coronary occlusion was produced by injecting 2.5 mm plastic beads into the coronary artery of the closed chest dog. Non-perfused myocardium, the area at risk, was visualised by autoradiography of 141Cerium labelled microspheres which were infused immediately following coronary embolization. The treated dogs (n = 12) received 400 mg of allopurinol orally one day before surgery. A 25 mg . kg-1 bolus was administered (iv) immediately before occlusion, and repeated every 8 h. 11 dogs served as controls. After 24 h, the dogs were killed and the hearts were sliced into 5.0 mm transverse sections. The infarcted myocardium was visualised by triphenyl tetrazolium chloride staining. The percentage of the risk zone which evolved to infarct was calculated. This percentage was 18.1 +/- 3.95% in the allopurinol group vs 58.4 +/- 2.81% in the control group (p less than 0.001). We conclude that allopurinol is a potent drug for the limitation of infarct size in the dog with permanent coronary occlusion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841027     DOI: 10.1093/cvr/19.11.686

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  22 in total

Review 1.  Inhibition of xanthine oxidase by allopurinol: a therapeutic option for ischaemia induced pathological processes?

Authors:  J G Puig; F A Mateos; V D Diaz
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

2.  Cytochemical evidence of NADH-oxidase activity in the isolated working rabbit heart subjected to normothermic global ischaemia.

Authors:  G Vandeplassche; F Thoné; M Borgers
Journal:  Histochem J       Date:  1990-01

Review 3.  Physiological aspects of percutaneous transluminal coronary angioplasty.

Authors:  H Kline
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

Review 4.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

5.  Allopurinol-enhanced myocardial protection does not involve xanthine oxidase inhibition or purine salvage.

Authors:  D J Chambers; A Takahashi; S M Humphrey; D M Harvey; D J Hearse
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

6.  Does the antiarrhythmic effect of DMPO originate from its oxygen radical trapping property or the structure of the molecule itself?

Authors:  A Tosaki; R F Haseloff; A Hellegouarch; K Schoenheit; V V Martin; D K Das; I E Blasig
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

7.  Endothelial superoxide production in the isolated rat heart during early reperfusion after ischemia. A histochemical study.

Authors:  C F Babbs; M D Cregor; J J Turek; S F Badylak
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

8.  Chronic administration of allopurinol fails to exert any cardioprotective effect in rats submitted to permanent coronary artery ligation.

Authors:  F Boucher; J de Leiris
Journal:  Basic Res Cardiol       Date:  1991 May-Jun       Impact factor: 17.165

9.  The protective action of allopurinol in an experimental model of haemorrhagic shock and reperfusion.

Authors:  G Allan; D Cambridge; L Lee-Tsang-Tan; C W Van Way; M V Whiting
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

Review 10.  The occurrence of oxidative stress during reperfusion in experimental animals and men.

Authors:  R Ferrari; C Ceconi; S Curello; A Cargnoni; E Pasini; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1991-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.